| Full Name | Hailey Alley |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 431 Marilyn Ln, Alcoa, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831754266 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 25748 (Tennessee) | Primary |
| Entity Name | Tennessee Vein Center, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598070807 PECOS PAC ID: 5193910057 Enrollment ID: O20101117000842 |
News Archive
Biodel Inc. today reported results of preclinical tests which demonstrated the potential of the company's glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, Nandini Kashyap, director of novel drug delivery at Biodel, described results of in vitro and in vivo studies with diabetic pigs which compared the use of BIOD620 to Lantus® (insulin glargine).
Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 12,150,000 shares of its common stock, at a price of $1.46 per share, and 12,150 shares of its Series C Convertible Preferred Stock, at a price of $1,460 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization.
PhotoMedex, the leader in photodamage repair technology, clinical skincare and medical laser products for more than a decade, introduces NEOVA® SmartSkinCare brand's DNA Barrier Accelerator, a hyper-active moisturizer that rehabilitates and fortifies the skin's essential protective barrier. DNA Barrier Accelerator is available for purchase in dermatology offices nationwide and on NEOVA.com.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hailey Alley, 8002 Ball Camp Pike, Knoxville, TN 37931-4037 Ph: (206) 818-7104 | Hailey Alley, 431 Marilyn Ln, Alcoa, TN 37701-2118 Ph: (865) 233-5858 |
News Archive
Biodel Inc. today reported results of preclinical tests which demonstrated the potential of the company's glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, Nandini Kashyap, director of novel drug delivery at Biodel, described results of in vitro and in vivo studies with diabetic pigs which compared the use of BIOD620 to Lantus® (insulin glargine).
Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 12,150,000 shares of its common stock, at a price of $1.46 per share, and 12,150 shares of its Series C Convertible Preferred Stock, at a price of $1,460 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization.
PhotoMedex, the leader in photodamage repair technology, clinical skincare and medical laser products for more than a decade, introduces NEOVA® SmartSkinCare brand's DNA Barrier Accelerator, a hyper-active moisturizer that rehabilitates and fortifies the skin's essential protective barrier. DNA Barrier Accelerator is available for purchase in dermatology offices nationwide and on NEOVA.com.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
› Verified 2 days ago
Melanie Bankerd, F.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 | |
Katherine Elizabeth Whittington, MSN, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 255 E Watt St, Alcoa, TN 37701 Phone: 865-273-1616 Fax: 865-273-1645 | |
Michael E Lowe, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 212 Heighton Ct, Alcoa, TN 37701 Phone: 865-556-2672 | |
Caytlin Grae Cardwell, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 255 E Watt St, Alcoa, TN 37701 Phone: 865-273-1616 Fax: 865-273-1645 | |
Mrs. Lori M. Ervin, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 | |
Lauren E Monroe, ANP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 | |
Summer Dobbs Brooks, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 |